Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Platinum compounds have shown activity in a broad spectrum of human tumors in vitro and in vivo. The clinical utility of platinum agents in gynecologic and gastrointestinal cancers (particularly oxaliplatin in colorectal cancer) has been well documented and platinum agents continue to be evaluated in a variety of other cancers. Given preclinical evidence of synergy among some platinum compounds and new anticancer agents, clinical trials exploring platinum-based combination therapies may yield improved treatment for a variety of malignancies. Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 14
DOIs
StatePublished - Dec 1 2004

Fingerprint

Platinum Compounds
Platinum
oxaliplatin
Breast Neoplasms
Lung
Urogenital Neoplasms
Neoplasms
Gastrointestinal Neoplasms
Antineoplastic Agents
Colorectal Neoplasms
Lung Neoplasms
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{be60c35497c148979d3e8cd73c726c91,
title = "Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma",
abstract = "Platinum compounds have shown activity in a broad spectrum of human tumors in vitro and in vivo. The clinical utility of platinum agents in gynecologic and gastrointestinal cancers (particularly oxaliplatin in colorectal cancer) has been well documented and platinum agents continue to be evaluated in a variety of other cancers. Given preclinical evidence of synergy among some platinum compounds and new anticancer agents, clinical trials exploring platinum-based combination therapies may yield improved treatment for a variety of malignancies. Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review.",
author = "Chandra Belani",
year = "2004",
month = "12",
day = "1",
doi = "10.1053/j.seminoncol.2004.11.005",
language = "English (US)",
volume = "31",
pages = "25--33",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 14",

}

TY - JOUR

T1 - Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma

AU - Belani, Chandra

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Platinum compounds have shown activity in a broad spectrum of human tumors in vitro and in vivo. The clinical utility of platinum agents in gynecologic and gastrointestinal cancers (particularly oxaliplatin in colorectal cancer) has been well documented and platinum agents continue to be evaluated in a variety of other cancers. Given preclinical evidence of synergy among some platinum compounds and new anticancer agents, clinical trials exploring platinum-based combination therapies may yield improved treatment for a variety of malignancies. Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review.

AB - Platinum compounds have shown activity in a broad spectrum of human tumors in vitro and in vivo. The clinical utility of platinum agents in gynecologic and gastrointestinal cancers (particularly oxaliplatin in colorectal cancer) has been well documented and platinum agents continue to be evaluated in a variety of other cancers. Given preclinical evidence of synergy among some platinum compounds and new anticancer agents, clinical trials exploring platinum-based combination therapies may yield improved treatment for a variety of malignancies. Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review.

UR - http://www.scopus.com/inward/record.url?scp=11344263608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11344263608&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.11.005

DO - 10.1053/j.seminoncol.2004.11.005

M3 - Article

C2 - 15726531

AN - SCOPUS:11344263608

VL - 31

SP - 25

EP - 33

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 14

ER -